US FDA Query Management (IRs/DRLs/CRLs)

Freyr offers expert ANDA query management services, ensuring timely and comprehensive responses to FDA deficiency letters. Our team provides strategic guidance, thorough assessments, and scientifically sound justifications to expedite generic drug approvals and market entry.

US FDA Query Management (IRs/DRLs/CRLs) - Overview

After the submission of the Abbreviated New Drug Application (ANDA), the USFDA may raise queries (Screening Deficiency/IRs/DRLs/CRL) to the ANDA holder for additional information/clarification on the content that has been included in the ANDA.

Response to the US FDA deficiency letters should be submitted on time with sufficient data and suitable scientific justifications to receive approval on the goal date for the ANDA.

Delay in response and inadequate response to the USFDA may warrant an additional round of deficiency letters and subsequently delay the approval and market entry. Hence, it is very important for the ANDA applicant to adequately respond to the USFDA queries.

Freyr, with strong expertise in generics registration activities, can provide support in the USFDA query management, along with the submission of a complete response, to the US FDA.

US FDA Query Management (IRs/DRLs/CRLs) - Expertise

  • Thorough review of the deficiencies received from the USFDA against registered content
  • Preparation of an action plan
  • Preparation of response strategy and guidance to the applicant on the activities to be performed
  • Assessment of additional data and/or inputs received from ANDA applicants and identifying the gaps
  • Preparation of response package with scientific justifications and supporting documents
  • Correspondence with FDA/guidance for extension request and negotiation on the strategy
US FDA Query Management (IRs/DRLs/CRLs)

Celebrating Customers Success

 

Medicinal Products

Regulatory Affairs

India

Thank you for the timely support over the weekend, which allowed us to resubmit quickly after being notified. This continuously demonstrates Freyr's commitment towards our company’s milestones.

Director - Global Regulatory Affairs – Operations

India-based, Global Top Generic Pharma Company

 

Medicinal Products

Publishing

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Sr. Director, Head of Regulatory Operations

Ireland-based, Global Specialty Pharmaceutical Company

 

Medicinal Products

Regulatory Affairs

USA

Please relate to the team the excellent job they have done on the IND reactivation. Specifically, the high-quality module 3, written by Freyr. It was very comprehensive, very few revisions were required, and we had no questions from Health Canada or FDA. No CMC questions: that was a first for me. So very responsive to my many requests, which I am sure can be frustrating but always helpful while producing excellent work.

Thank you for always being available and responding quickly and comprehensively to all my requests.

What a great team you have, Freyr.

Lynne McGrath

Regulatory Consultant

 

Medicinal Products

Regulatory Affairs

USA

Congratulations!!! ​

Thanks for your great support for a successful ANDA filing, especially to the publishing team. Heartfully appreciate their last hours of hard work.

Assistant Manager​

US-based, Leading, Complex Generic Pharmaceutical Products Company​

 

Medicinal Products

Regulatory Affairs

USA

Thank you all for the great support!​

CEO

US-based, Leading Innovative Pharmaceuticals Company​

 

Medicinal Products

Regulatory Affairs

USA

The ANDA receipt has been received! Thank you very much for your hard work, patience, and support for our work over the last couple of months. We are delighted that we were able to meet the timeline and hit an important corporate goal of our young company. ​

Thank you again, and we look forward to working with your team on the next project!

Senior Director of Business and Product Development​

US-based, Leading Innovator Pharmaceuticals Company​